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Drug eluting stents (DES) have had a great impact in reducing in-stent restenosis (ISR) in de 
novo lesions. However, long-term data regarding effectiveness and safety of these stents in 
treating bare metal stent (BMS) ISR are limited. We report long-term clinical outcomes in a 
cohort of patients with BMS-ISR treated with DES between April 2002 and December 2003 
at our institution. 
METHODS AND RESULTS:  
Sixty-nine consecutive patients with significant BMS-ISR were treated with DES 
implantation. Sirolimus DES were used in 43 patients and paclitaxel DES in 26. All patients 
were followed up to determine the incidence of major adverse cardiac event (MACE) rates 
(all-cause death, myocardial infarction, or target vessel revascularisation [TVR]), angina class 
and the need for clinically driven angiography. The mean age of the cohort was 58.6 ± 10.8 
years; 68% were male, 33% were diabetic, 50% had hypertension, 78% were on statin therapy 
and 59% were current (19%) or previous (41%) smokers. The clinical presentation of ISR was 
with chronic stable angina in 54 patients, 12 had a non-ST elevation acute coronary syndrome 
and three presented with ST-elevation myocardial infarction. Multivessel stenting was 
performed in 21 patients and bifurcation stenting in seven patients. Over a mean follow period 
of 4.9 years, the first event MACE rate was 20% (17 events in 14 patients - eight deaths of 
which three were cardiac, two non-fatal myocardial infarctions and seven TVR). Excluding 
non-cardiac death, the adjusted MACE rate was 14.5% (12 events in 10 patients). At long-
term follow-up, mean Canadian angina class decreased from 2.3 ± 0.7 pre-procedure to 1.2 ± 
0.4, 65% of patients were angina free and 80% were free of MACE. No differences in long-
term outcomes were observed between patients receiving paclitaxel and sirolimus DES. 
CONCLUSIONS:  
The use of DES for the treatment of BMS-ISR is safe and effective over a mean follow-up 
period of nearly five years. To our knowledge, this represents the longest follow-up data of 
real world patients treated in a single interventional centre. 
 
